Introduction: Hunan Kelun Pharmaceutical Co., Ltd. Yueyang Branch (hereinafter referred to as "Hunan Kelun Yueyang Branch") is a wholly-owned subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., ranking first in the province's pharmaceutical manufacturing industry The first square of enterprises ranks 76th among private enterprises in Hunan Province. In 2015, Hunan Kelun Yueyang Branch achieved main business income of more than 700 million yuan and paid taxes of 35.71 million yuan. In the first half of 2016, the main operating income was 380 million yuan, a year-on-year increase of 9%, and profits and taxes were more than 20 million yuan.
The company currently has more than 1,000 employees, with 10 major dosage forms, 96 varieties, 178 specifications, and 26 production lines, forming small-volume injections, lyophilized agents, powder injections, mixtures, capsules, With strong product clusters such as tablets, it is currently a comprehensive pharmaceutical company with a relatively complete range of pharmaceutical dosage forms and varieties in Central and South China. Among them, the production and sales scale of antibiotics ranks first in the country and first in the province; the key strategic variety of traditional Chinese medicine products? Kangfuxin Liquid is one of the traditional Chinese medicine varieties with sales of over 100 million in Hunan Province. In 2015, there were ***17 varieties in the pharmaceutical industry in Hunan Province with single product sales exceeding RMB 100 million, and Hunan Kelun Yueyang Branch accounted for 2 of them. In the next five years, Hunan Kelun's new drug segment will create more than 10 single products with sales of over 100 million.
The company now has 98 patents, two provincial innovation platforms, and has been identified as a high-tech enterprise in Hunan Province. It has been awarded the honorary titles of "Top 100 Private Enterprises in Hunan Province", "Environmental Integrity Enterprise in Hunan Province" and "National Model Enterprise with Harmonious Labor Relations".
The only way for enterprises to develop is through innovation. The research on the quality control system of Tianshuxin Rehabilitation New Liquid, a national second-class protected variety of traditional Chinese medicine and a famous trademark in Hunan Province, won the second prize of the Hunan Province Science and Technology Progress Award; the newly developed parecoxib sodium for injection was included in the 2013 Hunan Province Provincial industrial field? Hundreds of key new product promotion plans? Key new product research and development projects; Ligustrazine hydrochloride for injection was recognized as a national key new product by the Ministry of Science and Technology; the company's new drug product industrialization project was listed as a representative project of the province's pharmaceutical industry It is a key project dispatched by the governor of the Hunan Provincial Government; in June 2015, the new drug research and development and industrialization promotion project was approved by the Provincial Party Committee and the Provincial Government, and was included in the "Made in China 2025" action and the first batch of key projects in the construction of a strong manufacturing province in Hunan project.
Kelen Pharmaceutical took the lead in launching and implementing the Laboratory Information Management System (LIMS) project across the entire group, using computer systems to manage experiments and analyze data to ensure the accuracy and traceability of experiments. In September 2015, Kelun Pharmaceutical won the 2015 National Industrial Enterprise Quality Benchmark from the Ministry of Industry and Information Technology.
2. Company development plan During the 13th Five-Year Plan period, Hunan Kelun plans to build a tens-billion enterprise. In the next five years, Yueyang Branch will invest an additional 2 billion to 3 billion yuan, add more than 10 new production lines, and expect more than 50 new drug varieties to be approved. New drugs cover specialized treatment fields such as anti-tumor, anti-viral (HBV), mental and neurological diseases, and diabetes treatment drugs; the research and development of new drug delivery systems such as albumin nanoparticles, liposomes, microspheres, and microcrystals in the NDDS field Industrialization will be used as an innovation point to achieve targeted tumor treatment and improve product technology content and market share; at the same time, focusing on new rehabilitation liquids as key varieties, we will strengthen in-depth development, increase secondary development of indications, new dosage forms, etc., and expand its In functional fields such as medicinal and health care, we will build a breeding base in Tengchong, Yunnan, and improve the modern traditional Chinese medicine industry chain; within the two five-year plans, we will strive to achieve operating income of over 10 billion in 2025. In 2016, the first year of the 13th Five-Year Plan, Hunan Kelun Pharmaceutical Research Co., Ltd. settled in Yueyang Economic Development Zone. Currently, 118 major drugs that have been approved for research and development will be settled in the Economic Development Zone. Among them, 7 varieties and 10 specifications have obtained clinical approval, entered the clinical trial stage, and will be launched soon. The Drug Research Branch is also responsible for the research and development, pilot scale-up and industrialization of new drugs of Kelun Pharmaceutical. It cooperates with Sichuan Kelun Pharmaceutical Research Co., Ltd., Tianjin Kelun Pharmaceutical Research Co., Ltd., Suzhou Kelun Pharmaceutical Research Co., Ltd. and American Pharmaceuticals The research branch constitutes the five-in-one R&D system of Kelun Group and will become an important part of the R&D system of Kelun Group.
In 2016, Yueyang Branch plans to invest an additional 120 million yuan to build four new pilot production lines for anti-tumor products, including freeze-dried powder injections, small-volume injections, and solid preparations. The project will start at the end of July 2016 and is expected to be completed in the first quarter of 2017.
3. The process of making an enterprise bigger and stronger requires more soft services
The establishment and growth of Hunan Kelun Yueyang Branch has received support from provinces, cities, districts and various functions. The department provides high-quality services in many aspects, but to build the No. 1 drug dealer in Hunan, the century-old store needs to increase support at all levels and departments and introduce more preferential policies and other soft services.
1. Scientific and technological innovation leadership and support
Hunan Kelun has two production bases in Yueyang, which produce different types of Chinese and Western medicines. The two production bases are accounted for separately and report independently to the local government. Pay taxes.
In recent years, the company has been committed to the research and development of new drug delivery systems, including the research and development of nanoparticles, liposomes, microcrystals, etc., to achieve anti-tumor targeted therapy; at the same time, the company has applied for It has accepted hundreds of patents and invested a lot of manpower, material and financial resources in scientific and technological innovation. However, it can only apply as a subject in project application, and only accepts one single application every year. As a result, new technologies cannot be effectively promoted and given due attention.
It is hoped that the relevant functional departments of the municipal government will include the two production bases in Yueyang City's 37 designated assistance targets, receive recommendations and support in the application of scientific and technological innovation and other projects, and enjoy national project support policies. Provide strong support in applying for the Science and Technology Progress Award, key new product projects, and the Governor’s Quality Award.
2. Open a green channel for the construction of new projects
According to the new drug research and development process of Kelun Pharmaceutical, there will be more than ten varieties of new drug development pilot trials in 2016, which need to be carried out by the end of the year Therefore, the anti-tumor pilot line construction project must start construction in July this year and complete the civil construction in October. After discussion with the project design unit, it is planned to adopt the method of overall design, batch drawings, and step-by-step construction for construction. However, this method will cause the drawing time to meet the construction application conditions to be postponed to September this year.
In order to ensure that the project starts smoothly and is put into production as scheduled, we hereby sincerely request the Economic Development Zone Coordination Planning Bureau, Housing and Urban-Rural Development Bureau, Municipal Fire Brigade and other relevant departments to open a green channel for the preliminary infrastructure construction of the project.
3. Difficulties in fulfilling the policy of “retreating from the second level and advancing to the third level”
The former Hunan Zhongnan Kelun Pharmaceutical Co., Ltd. responded to the call of the “retreating from the second level and advancing to the third level” policy implemented by the municipal party committee and the municipal government. , the overall relocation was completed at the end of 2012. The old factory is located east of Desheng South Road and south of Jin'e West Road. Due to many reasons, it has not yet been listed for sale, and the benefits and policies that the company should enjoy cannot be fulfilled. Request the government's key support and convene a special meeting to coordinate and resolve the issue.
4. Support the introduction of talents and fully enjoy the preferential policies
In 2016, Yueyang Branch responded to the government’s “Talent Recruitment from All Seas” policy and accelerated the introduction of talents, and introduced only those with bachelor’s degrees and above. There are more than 80 academic personnel, including 15 master's degree candidates. However, most of them are fresh graduates, and some are students from other places. Since there are not many preferential policies to settle down in Yueyang, it is difficult to attract them to contribute to Yueyang for a long time. To this end, it is recommended that the municipal government introduce preferential policies for scientific and technological personnel to enjoy preferential public rental housing, and implement hierarchical preferential policies.
Legal representative: Liu Weiqiang
Date of establishment: 2012-04-25
Registered capital:
Region: Hunan Province
Unified social credit code: 91430600595464823J
Business status: Continuous (in operation, open, registered)
Industry: Manufacturing
Company type: Limited liability company branch (natural person investment or holding)
Staff size: 5000-9999 people
Company address: Qixi East Road, Kangwang Industrial Park, Yueyang Economic and Technological Development Zone
Business scope: Engage in business contacts within the company's business scope. (Projects that require approval according to law can only be carried out with approval from relevant departments)